|
1
|
Valente SA, Tendulkar RD, Cherian S,
O'Rourke C, Greif JM, Bailey L, Uhl V, Bethke KP, Donnelly ED,
Rudolph R, et al: TARGIT-R (Retrospective): North American
Experience with Intraoperative Radiation Using Low-Kilovoltage
X-Rays for Breast Cancer. Ann Surg Oncol. 23:2809–2815. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vaidya JS, Joseph DJ, Tobias JS, Bulsara
M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann
W, et al: Targeted intraoperative radiotherapy versus whole breast
radiotherapy for breast cancer (TARGIT-A trial): An international,
prospective, randomised, non-inferiority phase 3 trial. Lancet.
376:91–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Correa C, Harris EE, Leonardi MC, Smith
BD, Taghian AG, Thompson AM, White J and Harris JR: Accelerated
partial breast irradiation: Executive summary for the update of an
ASTRO evidence-based consensus statement. Pract Radiat Oncol.
7:73–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roberts MC, Miller DP, Shak S and Petkov
VI: Breast cancer-specific survival in patients with lymph
node-positive hormone receptor-positive invasive breast cancer and
Oncotype DX Recurrence Score results in the SEER database. Breast
Cancer Res Treat. 163:303–310. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network
Guidelines, B.C. NCCN guidelines version 2.2017 breast cancer.
2.2017 4.18.2017. https://www.nccn.org
|
|
6
|
Harris LN, Ismaila N, McShane LM, Andre F,
Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC,
Mennel RG, et al: Use of biomarkers to guide decisions on adjuvant
systemic therapy for women with early-stage invasive breast cancer:
American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 34:1134–1150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stemmer SM, Klang SH, Ben-Baruch N, Geffen
DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S and
Lieberman N: The impact of the 21-gene Recurrence Score assay on
clinical decision-making in node-positive (up to 3 positive nodes)
estrogen receptor-positive breast cancer patients. Breast Cancer
Res Treat. 140:83–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman
GH and Curtis LH: Initial trends in the use of the 21-gene
recurrence score assay for patients with breast cancer in the
Medicare population, 2005–2009. JAMA Oncol. 1:158–166. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lynch JA, Berse B, Coomer N and Kautter J:
21-gene recurrence score testing among Medicare beneficiaries with
breast cancer in 2010–2013. Genet Med. 19:1134–1143. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carlson JJ and Roth JA: The impact of the
Oncotype Dx breast cancer assay in clinical practice: A systematic
review and meta-analysis. Breast Cancer Res Treat. 141:13–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orucevic A, Bell JL, McNabb AP and Heidel
RE: Oncotype DX breast cancer recurrence score can be predicted
with a novel nomogram using clinicopathologic data. Breast Cancer
Res Treat. 163:51–61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gage MM, Rosman M, Mylander WC, Giblin E,
Kim HS, Cope L, Umbricht C, Wolff AC and Tafra L: A validated model
for identifying patients unlikely to benefit from the 21-gene
recurrence score assay. Clin Breast Cancer. 15:467–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oppong BA, Sen Gupta S, Gary M, Wehner P,
Mete M, Zhao D, Seevaratnam S, Rudra S and Willey SC: 21-gene
recurrence assay in patients receiving intraoperative radiotherapy:
Are ‘favorable’ characteristics a surrogate for low recurrence?
Gland Surg. 6:675–681. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Enewold L, Geiger AM, Zujewski J and
Harlan LC: Oncotype Dx assay and breast cancer in the United
States: Usage and concordance with chemotherapy. Breast Cancer Res
Treat. 151:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nguyen MT, Stessin A, Nagar H, D'Alfonso
TM, Chen Z, Cigler T, Hayes MK and Shin SJ: Impact of oncotype DX
recurrence score in the management of breast cancer cases. Clin
Breast Cancer. 14:182–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hershman DL, Kushi LH, Shao T, Buono D,
Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S and
Neugut AI: Early discontinuation and nonadherence to adjuvant
hormonal therapy in a cohort of 8,769 early-stage breast cancer
patients. J Clin Oncol. 28:4120–4128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brier MJ, Chambless DL, Gross R, Chen J
and Mao JJ: Perceived barriers to treatment predict adherence to
aromatase inhibitors among breast cancer survivors. Cancer.
123:169–176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Henry NL, Azzouz F, Desta Z, Li L, Nguyen
AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, et al:
Predictors of aromatase inhibitor discontinuation as a result of
treatment-emergent symptoms in early-stage breast cancer. J Clin
Oncol. 30:936–942. 2012. View Article : Google Scholar : PubMed/NCBI
|
